Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | PYGL | P06737 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716817 | 0.79 | POLB (0.42) | POLBKMT2ATSHRMEN1MAPK1 | |
| SCHEMBL6715474 | 0.78 | ALDH1A1 (0.48) | POLBEPHX2PYGLALDH1A1ALOX12 | |
| SCHEMBL6717325 | 0.77 | POLB (0.43) | POLBKMT2AEPHX2TSHRMEN1 | |
| SCHEMBL6723190 | 0.74 | KMT2A (0.51) | KMT2ATSHRMEN1PYGLALDH1A1 | |
| SCHEMBL6723576 | 0.74 | KMT2A (0.51) | KMT2ATSHRMEN1PYGLALDH1A1 | |
| SCHEMBL6718752 | 0.73 | MAPT (0.49) | KMT2AMEN1MAPK1ALDH1A1CYP1A2 | |
| SCHEMBL6716824 | 0.73 | MAPT (0.49) | KMT2AMEN1MAPK1ALDH1A1CYP1A2 | |
| SCHEMBL4011337 | 0.72 | POLB (0.50) | POLBKMT2ATSHRMEN1MAPK1 | |
| SCHEMBL6715754 | 0.72 | MAPT (0.46) | POLBKMT2ATSHRMEN1MAPK1 | |
| SCHEMBL6723390 | 0.71 | KMT2A (0.55) | KMT2AEPHX2TSHRMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| WO-2004022534-A1 | ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | POLB 4182/4885KMT2A 2020/4885EPHX2 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.